Sabby Management LLC acquired a new position in Interpace Diagnostics Gr (NASDAQ:IDXG) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,319,290 shares of the business services provider’s stock, valued at approximately $1,346,000. Sabby Management LLC owned 4.91% of Interpace Diagnostics Gr at the end of the most recent reporting period.
Separately, Virtu Financial LLC acquired a new stake in shares of Interpace Diagnostics Gr in the fourth quarter worth $133,000. Institutional investors and hedge funds own 13.61% of the company’s stock.
Interpace Diagnostics Gr (NASDAQ:IDXG) opened at $1.05 on Tuesday. The stock has a market cap of $28.19, a price-to-earnings ratio of -2.39 and a beta of 1.59. Interpace Diagnostics Gr has a twelve month low of $0.72 and a twelve month high of $4.45.
A number of analysts recently issued reports on the stock. Maxim Group set a $3.00 price target on shares of Interpace Diagnostics Gr and gave the stock a “buy” rating in a report on Friday. Laidlaw assumed coverage on shares of Interpace Diagnostics Gr in a report on Thursday, February 22nd. They set a “buy” rating and a $4.50 price target on the stock. ValuEngine raised shares of Interpace Diagnostics Gr from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Finally, HC Wainwright assumed coverage on shares of Interpace Diagnostics Gr in a report on Thursday, March 8th. They set a “buy” rating and a $3.00 price target on the stock.
WARNING: This story was published by Stock Observer and is owned by of Stock Observer. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.thestockobserver.com/2018/03/20/sabby-management-llc-acquires-shares-of-1319290-interpace-diagnostics-gr-idxg.html.
About Interpace Diagnostics Gr
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its proprietary PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay.
Receive News & Ratings for Interpace Diagnostics Gr Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Gr and related companies with MarketBeat.com's FREE daily email newsletter.